Grantham Mayo Van Otterloo & Co. LLC Sells 59,350 Shares of Solventum Co. (NYSE:SOLV)

Grantham Mayo Van Otterloo & Co. LLC lessened its holdings in Solventum Co. (NYSE:SOLV) by 10.7% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 494,160 shares of the company’s stock after selling 59,350 shares during the period. Grantham Mayo Van Otterloo & Co. LLC’s holdings in Solventum were worth $32,644,000 at the end of the most recent quarter.

A number of other hedge funds also recently bought and sold shares of SOLV. Modus Advisors LLC bought a new stake in shares of Solventum in the 4th quarter worth about $25,000. Stonebridge Financial Group LLC purchased a new stake in shares of Solventum in the fourth quarter worth approximately $26,000. Crews Bank & Trust purchased a new position in Solventum during the 4th quarter valued at $32,000. Synergy Asset Management LLC bought a new position in Solventum in the 4th quarter worth about $35,000. Finally, Spire Wealth Management purchased a new position in shares of Solventum during the fourth quarter worth approximately $37,000.

Solventum Stock Performance

Shares of SOLV stock opened at $66.22 on Friday. Solventum Co. has a 52-week low of $47.16 and a 52-week high of $85.92. The stock has a market cap of $11.45 billion and a PE ratio of 24.08. The business has a 50-day simple moving average of $75.42 and a 200-day simple moving average of $71.95. The company has a quick ratio of 0.83, a current ratio of 1.15 and a debt-to-equity ratio of 2.45.

Analyst Ratings Changes

Several research analysts have commented on the company. Wells Fargo & Company raised their price objective on Solventum from $73.00 to $75.00 and gave the stock an “equal weight” rating in a report on Friday, February 28th. Morgan Stanley upped their price objective on shares of Solventum from $73.00 to $80.00 and gave the stock an “equal weight” rating in a research note on Wednesday, March 5th. Piper Sandler raised their target price on shares of Solventum from $75.00 to $84.00 and gave the company a “neutral” rating in a research report on Friday, February 28th. Bank of America upped their price target on shares of Solventum from $80.00 to $85.00 and gave the stock a “neutral” rating in a research report on Wednesday, February 26th. Finally, Mizuho lifted their price objective on shares of Solventum from $70.00 to $82.00 and gave the company a “neutral” rating in a report on Monday, March 3rd. One research analyst has rated the stock with a sell rating, eight have assigned a hold rating and one has issued a buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $79.86.

Solventum Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.